Be Biopharma Launches With $52M Series A

Be Biopharma (‘Be Bio’), a leader in the development of B cells as medicines, founded by the Longwood Fund, David Rawlings, MD, and Richard James, PhD, today announced $52 million in Series A funding led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc. The company plans to use this funding to specifically engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at the Seattle Children’s Research Institute; B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have a wide, customizable functionality.

Be Biopharma is a leader in the development of B cells as medicines to treat human body disease in native protein factories. Precisely engineering B cells to use their inherent drug-like properties – remarkable protein production, selective tissue targeting, and fine-tuning of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues for stopping or reversing serious diseases such as cancer, autoimmune conditions and enzyme deficiency. Founded by the Longwood Fund and B Cell Engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy (bebiopharma) (com)

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Be%20Biopharma/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co